Brokerages expect Antares Pharma Inc (NASDAQ:ATRS) to post earnings per share of ($0.04) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Antares Pharma’s earnings. The highest EPS estimate is ($0.03) and the lowest is ($0.04). Antares Pharma posted earnings per share of ($0.03) during the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The company is scheduled to report its next earnings report on Tuesday, August 6th.
On average, analysts expect that Antares Pharma will report full-year earnings of ($0.10) per share for the current financial year, with EPS estimates ranging from ($0.13) to ($0.06). For the next fiscal year, analysts anticipate that the business will report earnings of $0.24 per share, with EPS estimates ranging from $0.00 to $0.60. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. The firm had revenue of $23.29 million for the quarter, compared to analyst estimates of $17.46 million.
NASDAQ:ATRS traded down $0.01 during midday trading on Thursday, reaching $2.85. The stock had a trading volume of 18,406 shares, compared to its average volume of 978,564. Antares Pharma has a 12-month low of $2.40 and a 12-month high of $3.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.28 and a quick ratio of 1.90. The firm has a market cap of $465.09 million, a price-to-earnings ratio of -71.50 and a beta of 1.03.
In other Antares Pharma news, Director Leonard S. Jacob sold 92,078 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $3.00, for a total transaction of $276,234.00. Following the sale, the director now directly owns 301,970 shares in the company, valued at approximately $905,910. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jacques Gonella sold 200,000 shares of the business’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $3.65, for a total transaction of $730,000.00. Following the sale, the director now owns 9,385,848 shares in the company, valued at $34,258,345.20. The disclosure for this sale can be found here. Insiders have sold a total of 322,078 shares of company stock worth $1,086,334 over the last 90 days. Insiders own 5.49% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of ATRS. BlackRock Inc. boosted its position in shares of Antares Pharma by 1.3% during the 3rd quarter. BlackRock Inc. now owns 9,929,257 shares of the specialty pharmaceutical company’s stock worth $33,362,000 after purchasing an additional 123,932 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Antares Pharma by 112.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 941,117 shares of the specialty pharmaceutical company’s stock worth $3,162,000 after purchasing an additional 497,523 shares in the last quarter. MetLife Investment Advisors LLC boosted its position in shares of Antares Pharma by 53.3% during the 3rd quarter. MetLife Investment Advisors LLC now owns 109,970 shares of the specialty pharmaceutical company’s stock worth $369,000 after purchasing an additional 38,239 shares in the last quarter. Morgan Stanley boosted its position in shares of Antares Pharma by 17.3% during the 3rd quarter. Morgan Stanley now owns 760,870 shares of the specialty pharmaceutical company’s stock worth $2,557,000 after purchasing an additional 112,221 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,487,465 shares of the specialty pharmaceutical company’s stock worth $21,798,000 after buying an additional 84,181 shares during the last quarter. Institutional investors own 40.66% of the company’s stock.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Further Reading: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.